WO2001003646A2 - High-volume on-line spectroscopic composition testing of manufactured pharmaceutical dosage units - Google Patents

High-volume on-line spectroscopic composition testing of manufactured pharmaceutical dosage units Download PDF

Info

Publication number
WO2001003646A2
WO2001003646A2 PCT/US2000/019273 US0019273W WO0103646A2 WO 2001003646 A2 WO2001003646 A2 WO 2001003646A2 US 0019273 W US0019273 W US 0019273W WO 0103646 A2 WO0103646 A2 WO 0103646A2
Authority
WO
WIPO (PCT)
Prior art keywords
spectral
pharmaceutical dosage
dosage units
image sensor
flow
Prior art date
Application number
PCT/US2000/019273
Other languages
French (fr)
Other versions
WO2001003646A3 (en
Inventor
E. Neil Lewis
David J. Strachan
Linda H. Kidder
Original Assignee
Spectral Dimensions, Inc.
The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/507,293 external-priority patent/US6690464B1/en
Application filed by Spectral Dimensions, Inc., The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services filed Critical Spectral Dimensions, Inc.
Priority to EP00950359A priority Critical patent/EP1218705A4/en
Publication of WO2001003646A2 publication Critical patent/WO2001003646A2/en
Publication of WO2001003646A3 publication Critical patent/WO2001003646A3/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84Systems specially adapted for particular applications
    • G01N21/88Investigating the presence of flaws or contamination
    • G01N21/95Investigating the presence of flaws or contamination characterised by the material or shape of the object to be examined
    • G01N21/9508Capsules; Tablets
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry

Definitions

  • This invention pertains to quality control systems and methods that detect process defects in large-scale manufacturing processes, such as the manufacture of pharmaceutical dosage units, using continuous spectral imaging techniques.
  • Defects in pharmaceutical products can be highly dangerous, or even fatal. And even if such defects are relatively minor, such as non-uniformly sized capsules, they can result in a significant loss of goodwill by the manufacturer. It is therefore of the utmost importance to avoid such defects.
  • Off-line methods include the testing of samples of reagents and end-products using various analytical methods.
  • On-line methods attempt to monitor the process of manufacturing the product to detect defects as they occur.
  • a number of on-line screening approaches currently exist.
  • One approach includes adding coloring agents to bulk ingredients and optically checking the shape, integrity, and color of the final product.
  • Systems employing this approach can take a series of video images of dosage units and use image processing methods to assess the shape and color of the dosage units.
  • Other systems employ groups of discrete optical detectors to detect different colors and infrared detectors to detect the scattering caused by structural defects. These systems can be complicated to install and maintain, and cannot guarantee a defect-free product.
  • the invention features a pharmaceutical dosage unit manufacturing process control apparatus that includes an image sensor including an array of detector elements located generally proximate a flow of pharmaceutical dosage units.
  • a spectrally selective element simultaneously projects a plurality of spectrally-discrete versions of a same image of the flow of pharmaceutical dosage units onto the image sensor.
  • a spectral processor is responsive to an output of the array sensor and having an output port.
  • the spectrally selective element can be a filter having filter characteristics that vary along the direction of flow of pharmaceutical dosage units.
  • the spectrally selective element can be a continuously gradeable filter.
  • the spectral processor can include a color mapping module operative to map spectral information into a color image including differently colored areas that correspond to different parts of the flow of pharmaceutical dosage units having differing responses to different wavelengths.
  • An additional processor can be operative to evaluate the differently colored areas, with the additional processor having an input responsive to the mapping module and an output for providing information about the areas.
  • the mapping module can be operative to shift a plurality of the wavelengths in a similar manner.
  • the spectral processor can include a spectral comparison module operative to compare spectral signatures from a library of known spectral signatures with spectral information acquired from the image sensor.
  • the spectral comparison module can be operative to perform spectral comparisons between the spectral information acquired from the image sensor and spectral signatures for known ingredients in a pharmaceutical composition of the dosage units.
  • the processor can be operative to receive, identify, and store newly detected spectral signatures reported by the spectral comparison module.
  • the library of known spectral signatures can include a plurality of spectral signatures for known defects.
  • the processor can be operative to receive, identify, and store spectral signatures for newly detected defects reported by the spectral comparison module.
  • the spectral processor can include a spectral comparison module operative to compare spectral information received by the image sensor from a reference sample located proximate the flow of pharmaceutical dosage units with spectral information received by the image sensor from the flow of pharmaceutical dosage units.
  • the image sensor can be a two-dimensional array sensor that further includes detectors located generally along an axis that is parallel to the direction of the flow of pharmaceutical dosage units.
  • the spectrally selective element can include a diffraction grating.
  • the spectral processor can include a color mapping module operative to map spectral information into a color image including differently colored areas that correspond to different parts of the flow of pharmaceutical dosage units having differing responses to different wavelengths.
  • the apparatus can further include an image processor responsive to the output port of the spectral processor and operative to evaluate information from the spectral processor.
  • the image sensor can be an infrared image sensor.
  • the image sensor can be a near infrared image sensor.
  • the apparatus can further include a radiation source directed at the flow of pharmaceutical dosage units at a position to which the array sensor is responsive.
  • the radiation source can be an infrared radiation source.
  • the flow of pharmaceutical dosage units can include a series of dosage units located in rows generally perpendicular to the direction of the flow of pharmaceutical dosage units and wherein the image sensor includes, for each of the dosage units in a row, a plurality of detectors along the axis that is perpendicular to the direction of the flow of pharmaceutical dosage units.
  • the spectral processor can be a real-time processor operative to process the images at a rate that is at least equal to a rate at which images are acquired by the image sensor.
  • the spectral processor can be operative to sequentially process spectral data for each line image acquired by the image sensor.
  • the spectral processor can be operative to receive image data from the image sensor at a rate that is independent of a rate of advance of the flow of pharmaceutical dosage units.
  • the spectral processor can be operative to receive image data from the image sensor at a rate that is independent of a rate of advance of the flow of pharmaceutical dosage units.
  • the spectral processor can be operative to perform univariate spectral manipulations on a spectral data set acquired from the image sensor.
  • the spectral processor can be operative to perform multivariate spectral manipulations on a spectral data set acquired from the image sensor.
  • the invention features a pharmaceutical dosage unit manufacturing process control apparatus that includes means for simultaneously projecting a plurality of spectrally-discrete versions of a same image of a flow of pharmaceutical dosage units onto an image sensor, and means for processing the images acquired by the means for acquiring.
  • the means for simultaneously projecting can include a filter having filter characteristics that vary along the direction of flow of pharmaceutical dosage units.
  • the invention features a pharmaceutical dosage unit manufacturing process control method that includes simultaneously projecting a plurality of spectrally-discrete versions of a same image of a flow of pharmaceutical dosage units onto an image sensor, acquiring a plurality of multi-pixel images of the flow of pharmaceutical dosage units, processing the images acquired in the step of acquiring, and providing an indication about the flow of pharmaceutical dosage units based on the step of processing.
  • the step of simultaneously projecting can include a step of filtering.
  • the invention features a pharmaceutical dosage unit manufacturing process control apparatus.
  • This apparatus comprises an image sensor including an array of detector elements located generally along an axis that is perpendicular to a direction of a flow of pharmaceutical dosage units.
  • a spectrally selective element is located in an optical path between a radiation source, the flow of pharmaceutical dosage units, and the image sensor.
  • a spectral processor is responsive to an output of the image sensor and having an output port.
  • the spectral processor can include a color mapping module operative to map spectral information into a color image including differently colored areas that correspond to different parts of the flow of pharmaceutical dosage units having differing responses to different wavelengths.
  • An additional processor can be operative to evaluate the differently colored areas, with the additional processor having an input responsive to the mapping module and an output for providing information about the areas.
  • the mapping module can be operative to shift a plurality of the wavelengths in a similar manner.
  • the spectral processor can include a spectral comparison module operative to compare spectral signatures from a library of known spectral signatures with spectral information acquired from the image sensor.
  • the spectral comparison module can be operative to perform spectral comparisons between the spectral information acquired from the image sensor and spectral signatures for known ingredients in a pharmaceutical composition of the dosage units.
  • the processor can be operative to receive, identify, and store newly detected spectral signatures reported by the spectral comparison module.
  • the library of known spectral signatures can include a plurality of spectral signatures for known defects.
  • the processor can be operative to receive, identify, and store spectral signatures for newly detected defects reported by the spectral comparison module.
  • the spectral processor can include a spectral comparison module operative to compare spectral information received by the image sensor from a reference sample located proximate the flow of pharmaceutical dosage units with spectral information received by the image sensor from the flow of pharmaceutical dosage units.
  • the image sensor can be a two-dimensional array sensor that further includes detectors located generally along an axis that is parallel to the direction of the flow of pharmaceutical dosage units.
  • the spectrally selective element can include a diffraction grating.
  • the spectral processor can include a color mapping module operative to map spectral information into a color image including differently colored areas that correspond to different parts of the flow of pharmaceutical dosage units having differing responses to different wavelengths.
  • An image processor can be responsive to the output port of the spectral processor and operative to evaluate information from the spectral processor.
  • the image sensor can be an infrared image sensor.
  • the image sensor can be a near infrared image sensor.
  • the radiation source can be directed at the flow of pharmaceutical dosage units at a position to which the image sensor is responsive.
  • the flow of pharmaceutical dosage units can include a series of dosage units located in rows generally perpendicular to the direction of the flow of pharmaceutical dosage units, with the image sensor including, for each of the dosage units in a row, a plurality of detectors along the axis that is perpendicular to the direction of the flow of pharmaceutical dosage units.
  • the spectral processor can be a real-time processor operative to process the images at a rate that is at least equal to a rate at which images are acquired by the image sensor.
  • the spectral processor can be operative to sequentiall -process spectral data for each line image acquired by the image sensor.
  • the spectral processor can be operative to receive image data from the image sensor at a rate that is independent of a rate of advance of the flow of pharmaceutical dosage units.
  • the spectral processor can be operative to receive image data from the image sensor at a rate that is independent of a rate of advance of the flow of pharmaceutical dosage units.
  • the spectral processor can be operative to perform univariate spectral manipulations on a spectral data set acquired from the image sensor.
  • the spectral processor can be operative to perform multivariate spectral manipulations on a spectral data set acquired from the image sensor.
  • the spectrally selective element can be a filter having filter characteristics that vary along the direction of flow of pharmaceutical dosage units.
  • the spectrally selective element can be a continuously gradeable filter.
  • the spectrally selective element can include a system that simultaneously projects a plurality of spectrally-discrete versions of a same image onto the image sensor.
  • the invention features a pharmaceutical dosage unit manufacturing process control apparatus that includes means for acquiring a plurality of multi- pixel images of a flow of pharmaceutical dosage units at different wavelengths along an axis that is perpendicular to a direction of the flow of pharmaceutical dosage units, and means for processing the images acquired by the means for acquiring.
  • the invention features a pharmaceutical dosage unit manufacturing process control method including acquiring a plurality of multi-pixel images of a flow of pharmaceutical dosage units at different wavelengths along an axis that is perpendicular to a direction of the flow of pharmaceutical dosage units, processing the images acquired in the step of acquiring, and providing an indication about the flow of pharmaceutical dosage units based on the step of processing.
  • the invention features a pharmaceutical dosage unit manufacturing process control apparatus that includes means for acquiring a plurality of multi- pixel line images of a flow of pharmaceutical dosage units along an axis that is perpendicular to a direction of the flow of pharmaceutical dosage units, and means for processing the images acquired in the step of acquiring as they are received.
  • the means for acquiring can be operative to acquire the multi-pixel line images at a rate that is independent of a rate of advance of the flow of pharmaceutical dosage units.
  • the invention features a pharmaceutical dosage unit manufacturing process control method that includes acquiring a plurality of multi-pixel line images of a flow of pharmaceutical dosage units along an axis that is perpendicular to a direction of the flow of pharmaceutical dosage units, processing the images acquired in the step of acquiring as they are received, and providing an indication about the rrow of pharmaceutical dosage units based on the step of processing.
  • the step of acquiring can be operative to acquire the multi- pixel line images at a rate that is independent of a rate of advance of the flow of pharmaceutical dosage units.
  • the step of acquiring can take place through individual packaging cells for the dosage units.
  • the invention features a process control apparatus that includes means for acquiring a spectral data set from a process flow, the spectral data set expressing the response of areas of a surface of the process flow to different wavelengths of radiation, and means for mapping the spectral data set to a color image including differently colored areas that correspond to different ones of the parts of the process flow having differing responses to the different wavelengths.
  • the apparatus further includes means for evaluating the differently colored areas, having an input responsive to the means for mapping and an output for providing information about the areas.
  • the invention features a process control method that includes acquiring a spectral data set from a process flow, the spectral data set expressing the response of areas of a surface of the process flow to different wavelengths of radiation, and mapping the spectral data set to a color image including differently colored areas that correspond to different ones of the parts of the process flow having differing responses to the different wavelengths.
  • the invention features a process control apparatus that includes an image sensor including an array of detector elements located generally along an axis that is pe ⁇ endicular to a direction of a process flow, a spectrally selective element located in an optical path between a radiation source, the flow of pharmaceutical dosage units, and the image sensor, and a spectral processor responsive to an output of the image sensor and having an output port, the spectral processor including a spectral comparison module operative to compare spectral signatures from a library of known spectral signatures with spectral information acquired from the image sensor.
  • the processor can be operative to receive, identify, and store spectral signatures for newly detected defects reported by the spectral comparison module.
  • the spectral comparison module can be operative to perform spectral comparisons between the spectral information acquired from the image sensor and spectral signatures for known defects.
  • the spectral comparison module can be operative to perform spectral comparisons between the spectral information acquired from the image sensor and spectral signatures for known ingredients in a pharmaceutical composition of the dosage units.
  • the invention features a process control apparatus that includes means for acquiring a plurality of multi-pixel images of a process flow at different wavelengths along an axis that is pe ⁇ endicular to a direction of the process flow, and means for comparing spectral signatures from a library of known spectral signatures with spectral information acquired in the step of acquiring.
  • the means for comparing can be operative to receive, identify, and store spectral signatures for new defects detected by the means for comparing.
  • the means for comparing can be operative to compare spectral signatures for known defects with the spectral information acquired in by the means for acquiring,
  • the invention features a process control method that includes acquiring a plurality of multi-pixel images of a process flow at different wavelengths along an axis that is pe ⁇ endicular to a direction of the process flow, comparing spectral signatures from a library of known spectral signatures, including a plurality of spectral signatures for known defects, with spectral information acquired in the step of acquiring, and providing an indication about the flow of pharmaceutical dosage units based on the step of processing.
  • the method further includes the steps of automatically identifying and storing spectral signatures for new defects detected in the step of comparing.
  • the step of comparing can be operative to compare spectral signatures for known defects with the spectral information acquired in the step of acquiring,
  • the invention features a quality control apparatus for a pharmaceutical composition that includes a two-dimensional array sensor including a two- dimensional array of detector elements, a spectrally selective element located in an optical path between a radiation source, the flow of pharmaceutical dosage units, and the two-dimensional array sensor, and a spectral processor responsive to an output of the array sensor and having an output port.
  • the spectral processor includes a mapping module operative to map spectral information into an image including different areas corresponding to different components of the pharmaceutical composition having differing responses to different wavelengths.
  • the spectral processor can include a spectral comparison module operative to compare one or more known spectral signatures with spectral information acquired from the array sensor.
  • the spectral comparison module can be operative to perform spectral comparisons between the spectral information acquired from the array sensor and spectral signatures for at least one known ingredient in the pharmaceutical composition.
  • the spectral comparison module can be operative to perform spectral comparisons between the spectral information acquired from the array sensor and spectral signatures for a plurality of known ingredients in the pharmaceutical composition.
  • the spectral processor can include a spectral comparison module operative to compare spectral information received by the array sensor from a reference sample with spectral information received by the array sensor.
  • the spectrally selective element can include a diffraction grating.
  • the apparatus can further include an image processor responsive to the output port of the spectral processor and operative to evaluate information from the spectral processor.
  • the array sensor can be an infrared image sensor.
  • the array sensor can be a near infrared image sensor.
  • the radiation source can be directed at the pharmaceutical composition at a position to which the array sensor is responsive.
  • the radiation source can be an infrared radiation source.
  • the spectral processor can be operative to perform spectral manipulations on a spectral data set that includes image values at different wavelengths for each of a plurality of pixels corresponding to ones of the detector elements in the detector array.
  • the quality control apparatus can be part of an on-line monitoring apparatus that continuously monitors a moving process web.
  • the quality control apparatus can be operative to detect product defects that include non-uniformity of a size of capsules transported by the web.
  • the quality control apparatus can be operative to detect product defects that include contamination or damage.
  • the quality control apparatus can be operative to detect product defects that include product non-uniformity.
  • the mapping module can be a color mapping module.
  • the apparatus can further include an additional processor operative to evaluate the different areas, with the additional processor having an input responsive to the mapping module and an output for providing information about the areas.
  • the spectral processor can be operative to perform univariate spectral manipulations on a spectral data set acquired from the array sensor.
  • the spectral processor can be operative to perform multivariate spectral manipulations on a spectral data set acquired from the array sensor.
  • the spectrally selective element can include a system that simultaneously projects a plurality of spectrally-discrete versions of a same image onto the array sensor.
  • the invention features a quality control apparatus for a pharmaceutical composition that includes means for acquiring a two-dimensional spectral data set expressing the response of areas of a surface to different wavelengths of radiation, and means for mapping the spectral data set to an image including different areas that correspond to different components of the pharmaceutical composition having differing responses to different wavelengths.
  • the means for acquiring can include means for selecting spectral components of radiation received from ingredients of the pharmaceutical composition.
  • the means for processing can include means for comparing spectral signatures from a library of known spectral signatures with spectral information acquired in the step of acquiring.
  • the invention features a quality control method for a pharmaceutical composition that includes acquiring a spectral data set expressing the response of areas of a surface to different wavelengths of radiation, and mapping the spectral data set to a color image including differently colored areas that correspond to different ones of the parts of surface having differing responses to the different wavelengths.
  • the method can further include the step of comparing spectral signatures from a library of known spectral signatures including signatures for one or more components of the pharmaceutical composition.
  • Systems according to the invention are advantageous in that they can continuously test the actual composition of each dosage unit within its packaging. Such systems can therefore screen for errors in coloring of ingredients, for contamination or breakdown that occurs independent of coloring, and for other types of errors that might not otherwise be detected. And because systems according to the invention can perform their composition measurements through the end-user package walls, they can detect contamination or damage that occurs during packaging.
  • composition analysis by comparing spectral information with libraries of known spectral signatures allows small concentrations of potentially dangerous contaminants, such as potent toxins, to be detected. Without being correlated to a specific spectral signature, such small concentrations might have little effect on prior art process monitoring methods, and might therefore be dismissed as within an error margin.
  • composition analysis by comparing spectral information with libraries of known spectral signatures may also allow for the detection of unexpected components. Comparing acquired spectral information with libraries of components may uncover contaminants not normally associated with the process. This may allow a manufacturer to avert hazards that arise out of unforseen circumstances, such as supplier errors or deliberate tampering.
  • composition analysis by comparing spectral information with libraries of known spectral signatures may further allow for the detection of subtle shifts in the process. Because relative quantities of ingredients can be directly measured, a change in the ratio of these ingredients can be detected. While such changes may not warrant rejection of the products, they may allow the process to be optimized and prevent the process from drifting out of its intending operating range.
  • Systems according to the invention may also be advantageous in that they can allow a process engineer to select optimal process variables to monitor.
  • systems according to the invention can apply the image processing resources to the spectrat data that correlates best to known and predicted failure modes. And because the system acquires information about a large number of wavelengths simultaneously, a system operator can try a number of different approaches to achieve the best results.
  • Fig. 1 is a diagram of an embodiment of a pharmaceutical dosage unit manufacturing process control system according to the invention, including a perspective portion illustrating the relationship between the image sensor, the spectrally selective element, and the process stream;
  • Fig. 2 is a plan view diagram of an image sensor for use with the process control system of Fig. 1;
  • Fig. 3 is a plan view diagram illustrating output of the system of Fig. 1;
  • Fig. 4 is a flowchart illustrating the operation of the embodiment of Fig. 1;
  • Fig. 5 is a diagram of a second embodiment of a pharmaceutical dosage unit manufacturing process control system according to the invention, including a perspective portion illustrating the relationship between the image sensor, the spectrally selective element, and the process stream.
  • a pharmaceutical dosage unit manufacturing process control system features an image sensor 10 and a spectrally selective element 12 facing a web 16 that carries a series of parallel rows of pharmaceutical dosage units 18, such as capsules, tablets, pellets, ampoules, or vials, in a process flow direction.
  • the web can carry a continuous stream of blister-packaged tablets from the output of a packaging machine.
  • the image sensor is a multi-element sensor that includes at least a series of adjacent sensing elements located generally along an axis that is pe ⁇ endicular to the flow direction.
  • the spectrally selective element is a wavelength separating element, and is preferably a dispersive element, such as a diffraction grating or a prism-based monochromator.
  • the image sensor 10 is preferably a two-dimensional array sensor that includes a two-dimensional array of detector elements made up of a series of lines of elements (Al - An, Bl - Bn, ... Nl - Nn) that are each located generally along an axis that is pe ⁇ endicular to the flow direction.
  • the image sensor can include an array of integrated semiconductor elements, such as a Charge-Coupled Device (CCD) array, and is preferably sensitive to infrared radiation.
  • CCD Charge-Coupled Device
  • Uncooled Idium-Galium-Arsenide (InGaAs) arrays, which are sensitive to near infrarrd wavelengths, are suitable image sensors, alnrough sensitivity to longer wavelengths would be desirable.
  • the sensors should preferably have dimensions of at least 64 x 64 or even 256 x 256. Where such sensors are not square, they should be oriented with their longer dimension in the direction of the process flow, as spectral information appears to be typically more important than spatial information given the nature of pharmaceutical mass-production equipment.
  • the system also includes an image acquisition interface 22 having an input port responsive to an output port of the image sensor 10.
  • the image acquisition interface receives and/or formats image signals from the image sensor. It can include an off-the shelf frame buffer card with a 12-16 bit dynamic range, such as are available from Matrox Electronic Systems Ltd. of Montreal, Canada, and Dipix Technologies, of Ottawa, Canada.
  • a spectral processor 26 has an input responsive to the image acquisition interface 22. This spectral processor has a control output provided to a source control interface 20, which can power and control an illumination source 14.
  • the illumination source for near infrared measurements is preferably a Quartz-Tungsten-Halide lamp.
  • the spectral processor 26 is also operatively connected to a standard input/output (IO) interface 30 and to a local spectral library 24.
  • the local spectral library includes locally-stored spectral signatures for known process components. These components can include ingredients, process products, or results of process defects or contamination.
  • the IO interface can also operatively connect the spectral processor to a remote spectral library 28.
  • the spectral processor 26 is operatively connected to an image processor 32 as well.
  • the image processor can be an off-the-shelf programmable industrial image processor, that includes special-pu ⁇ ose image processing hardware and image evaluation routines that are operative to evaluate shapes and colors of manufactured objects in industrial environments. Such systems are available from, for example, Cognex, Inc.
  • the system is based on the so-called IBM-PC architecture.
  • the image acquisition interface 22, IO interface 30, and image processor 32 each occupy expansion slots on the system bus.
  • the spectral processor is implemented using special-pu ⁇ ose spectral processing routines loaded on the host processor, and the local spectral library is stored in local mass storage, such as disk storage.
  • other structures can be used to implement systems according to the invention, including various combinations of dedicated hardware and special-pu ⁇ ose software running on general-pu ⁇ ose hardware.
  • the various elements and steps described can be reorganized, divided, and combined in different ways without departing from the scope and spirit of the invention. For example, many of the separate operations described arjove can be performed simultaneously according to well-known pipelining and parallel processing principles.
  • the spectrally selective element 12 is sensitive to the radiation reflected off of a line across the process web 16, and collimated by a first-stage optic, such as a lens (not shown).
  • the spectrally selective element separates the spectral components of the reflected radiation along the axis of the process flow.
  • the successive lines Al - An, Bl - Bn, ... Nl - Nn of the image sensor are exposed to spectral components of the radiation that are of successively higher or lower wavelengths, depending on the relative orientation of the spectrally selective element and the image sensor.
  • a portion of the line image extends beyond the web to overlap with a stationary reference sample 19 located adjacent the web. This implementation can allow for the removal of transfer of calibration requirements between systems that collect pure component, spectra for spectral comparison.
  • the image acquisition interface 22 acquires a data set representative of the radiation incident on the image sensor (i.e., a spectral line image — step 40).
  • This data set includes image values for each of the pixels along the imaged line on the process web at a number of different wavelengths. In the case of a 256 x 256 array, intensity values at 256 different wavelengths will be stored for each of 256 points on the imaged line.
  • the image acquisition interface transfers this data set to the spectral processor 26.
  • the spectral processor 26 then evaluates the acquired spectral line image (step 42).
  • This evaluation can include a variety of univariate and multivariate spectral manipulations. These can include comparing received spectral information with spectral signatures stored in the library, comparing received spectral information attributable to manufactured dosage units with information attributable to the reference sample, or evaluating simplified test functions, such as looking for the absence of a particular wavelength or combination of wavelengths. Multivariate spectral manipulations are discussed in more detail in "Multivariate Image Analysis,” by Paul Geladi and Hans, Grahn, available from John Wiley, ISBN No. 0-471-93001-6, which is herein inco ⁇ orated by reference.
  • the spectral processor 26 may detect known components (step 44) and or unknown components (step 46). If an unknown component is detected, the system records a spectral signature entry for the new component type in the local spectral library 24 (step 48). The system can also attempt to identify the newly detected component in an extended or remote library 28, such as by accessing it through a telephone line or computer network (step 50). The system then flags the detection of the new component to the system operator, and reports any retrieved candidate identities (step 52). Once component identification is complete, the system maps ffle different detected components into a color (such as grayscale) line image (step 54). As the system processes further spectral line images, it accumulates a two-dimensional colored image frame. When complete, this image can be transferred to the image processor (step 58), which evaluates the shape and color of the dosage units (step 60), issues rejection signals for rejected dosage units, and compiles operation logs.
  • the image processor step 58
  • the color image will resemble the process web, although it may be stretched or squeezed in the direction of the process flow, depending on the acquisition rate.
  • the image can include a color that represents the composition of the web 16. It will can also include colors that represent known good components 18A, colors that represent known defect components 18B, and colors that represent unknown components 18C.
  • the mapping can also take the form of a spectral shift, in which some or all of the acquired spectral components are shifted in a similar manner, preserving the relationship between wavelengths. Note that because the image maps components to colors, it provides information about spatial distribution of the pharmaceutical composition in addition to identifying its components.
  • While the system can operate in real-time to detect defective products, its results can also be analyzed further off-line. For example, some or all of the spectral data sets, or running averages derived from these data sets can be stored and periodically compared with extensive off-line databases of spectral signatures to detect possible new contaminants. Relative spectral intensities arising from relative amounts of reagents or ingredients can also be computed to determine if the process is optimally adjusted.
  • the system presented above is self-scanning. Although it can be synchronized with the process by a sensor, such synchronization is not required. The system can therefore be easily retrofit to existing installations and does not require any moving parts.
  • the acquisition method employed by the process control system can also be computationally efficient. Since data is acquired and spectrally processed on a line-by-line basis, the spectral processor does not have to store large amounts of intermediate results. Once a line has been mapped to a colored line image, all of the acquired data and intermediate results can be discarded, and a new line processed. This can allow the system to operate in real time with relatively simple computer components, keeping the overall system cost low.
  • a second embodiment of a pharmaceutical dosage unit manufacturing process control system includes a variable-bandpass filter 12a between the two-dimensional array sensor and the process stream.
  • This filter has a narrow pass- band with a center wavelength that varies along the process direction.
  • the leading edge A of the filter passes shorter wavelengths, and as the distance from the leading edge along the process flow direction increases, the filter passes successively longer wavelengths.
  • the filter passes a narrow range of the longest wavelengths.
  • the orientation of the filter can also be reversed, so that the pass-band center wavelength decreases along the process flow direction.
  • the filter has been illustrated as a series of strips located pe ⁇ endicular to the process flow direction, it can be manufactured in practice by continuously varying the dielectric thickness in an interference filter.
  • the filter should have a range of pass- bands that matches the range of the camera. Suitable filters are available, for example, from Optical Coatings Laboratory, Inc. of Santa Rosa, California.
  • acquisition interface 22 acquires data representing a series of variably- filtered, two-dimensional images. These two-dimensional images each include image values for the pixels in a series of adjacent lines pe ⁇ endicular to the process web. Because of the action of the variable-bandpass filter, the detected line images that make up each two-dimensional image will have a spectral content that varies along the process direction.
  • the variably filtered images are combined as they are acquired in order to obtain full- range spectral images.
  • each successive line ( l ... Al) of elements in the array sensor 10 will sense radiation that has been filtered through a corresponding line (N ... A) of the filter.
  • These individual line images can be assembled to create a full-spectrum line image.
  • the assembly can take place by itself, or in combination with other operations, such as digital filtering operations. This embodiment is particularly advantageous because the variable-bandpass filter is relatively inexpensive and robust.
  • a further embodiment employs multi-source arrays to provide successive illumination at different wavelengths and thereby obtain spectral information from the process.
  • multi-source arrays are described in a copending provisional application entitled “Multi-Source Arrays,” filed on the same day as this application, and herein inco ⁇ orated by reference.

Abstract

A pharmaceutical dosage unit manufacturing process control apparatus is disclosed. This apparatus includes an image sensor (10), including an array of detector elements, located generally proximate a flow of pharmaceutical dosage units (18). A spectrally selective element (12) simultaneously projects a plurality of spectrally-discrete versions of a same image of the flow of pharmaceutical dosage units onto the image sensor. A spectral processor is responsive to an output of the image sensor.

Description

HIGIF-VOLUME ON-LINE SPECTROSCOPICTOMPOSITION TESTING OF MANUFACTURED PHARMACEUTICAL DOSAGE UNITS
Field of the Invention
This invention pertains to quality control systems and methods that detect process defects in large-scale manufacturing processes, such as the manufacture of pharmaceutical dosage units, using continuous spectral imaging techniques.
Background of the Invention
Defects in pharmaceutical products can be highly dangerous, or even fatal. And even if such defects are relatively minor, such as non-uniformly sized capsules, they can result in a significant loss of goodwill by the manufacturer. It is therefore of the utmost importance to avoid such defects.
Several approaches now exist to screen pharmaceutical agents packaged in predetermined dosage units, such as capsules or tablets. These include off-line and on-line methods. Off-line methods include the testing of samples of reagents and end-products using various analytical methods. On-line methods attempt to monitor the process of manufacturing the product to detect defects as they occur.
A number of on-line screening approaches currently exist. One approach includes adding coloring agents to bulk ingredients and optically checking the shape, integrity, and color of the final product. Systems employing this approach can take a series of video images of dosage units and use image processing methods to assess the shape and color of the dosage units. Other systems employ groups of discrete optical detectors to detect different colors and infrared detectors to detect the scattering caused by structural defects. These systems can be complicated to install and maintain, and cannot guarantee a defect-free product.
Summary of the Invention
Several aspects of the invention are presented in this application. These relate to improvements to process control apparatus and methods, including apparatus and methods that detect process defects in large-scale manufacturing processes, such as the manufacture of pharmaceutical dosage units, using continuous spectral imaging techniques.
In one general aspect, the invention features a pharmaceutical dosage unit manufacturing process control apparatus that includes an image sensor including an array of detector elements located generally proximate a flow of pharmaceutical dosage units. A spectrally selective element simultaneously projects a plurality of spectrally-discrete versions of a same image of the flow of pharmaceutical dosage units onto the image sensor. A spectral processor is responsive to an output of the array sensor and having an output port.
In preferred embodiments, the spectrally selective element can be a filter having filter characteristics that vary along the direction of flow of pharmaceutical dosage units. The spectrally selective element can be a continuously gradeable filter. The spectral processor can include a color mapping module operative to map spectral information into a color image including differently colored areas that correspond to different parts of the flow of pharmaceutical dosage units having differing responses to different wavelengths. An additional processor can be operative to evaluate the differently colored areas, with the additional processor having an input responsive to the mapping module and an output for providing information about the areas. The mapping module can be operative to shift a plurality of the wavelengths in a similar manner. The spectral processor can include a spectral comparison module operative to compare spectral signatures from a library of known spectral signatures with spectral information acquired from the image sensor. The spectral comparison module can be operative to perform spectral comparisons between the spectral information acquired from the image sensor and spectral signatures for known ingredients in a pharmaceutical composition of the dosage units. The processor can be operative to receive, identify, and store newly detected spectral signatures reported by the spectral comparison module. The library of known spectral signatures can include a plurality of spectral signatures for known defects. The processor can be operative to receive, identify, and store spectral signatures for newly detected defects reported by the spectral comparison module. The spectral processor can include a spectral comparison module operative to compare spectral information received by the image sensor from a reference sample located proximate the flow of pharmaceutical dosage units with spectral information received by the image sensor from the flow of pharmaceutical dosage units. The image sensor can be a two-dimensional array sensor that further includes detectors located generally along an axis that is parallel to the direction of the flow of pharmaceutical dosage units. The spectrally selective element can include a diffraction grating. The spectral processor can include a color mapping module operative to map spectral information into a color image including differently colored areas that correspond to different parts of the flow of pharmaceutical dosage units having differing responses to different wavelengths. The apparatus can further include an image processor responsive to the output port of the spectral processor and operative to evaluate information from the spectral processor. The image sensor can be an infrared image sensor. The image sensor can be a near infrared image sensor. The apparatus can further include a radiation source directed at the flow of pharmaceutical dosage units at a position to which the array sensor is responsive. The radiation source can be an infrared radiation source. The flow of pharmaceutical dosage units can include a series of dosage units located in rows generally perpendicular to the direction of the flow of pharmaceutical dosage units and wherein the image sensor includes, for each of the dosage units in a row, a plurality of detectors along the axis that is perpendicular to the direction of the flow of pharmaceutical dosage units. The spectral processor can be a real-time processor operative to process the images at a rate that is at least equal to a rate at which images are acquired by the image sensor. The spectral processor can be operative to sequentially process spectral data for each line image acquired by the image sensor. The spectral processor can be operative to receive image data from the image sensor at a rate that is independent of a rate of advance of the flow of pharmaceutical dosage units. The spectral processor can be operative to receive image data from the image sensor at a rate that is independent of a rate of advance of the flow of pharmaceutical dosage units. The spectral processor can be operative to perform univariate spectral manipulations on a spectral data set acquired from the image sensor. The spectral processor can be operative to perform multivariate spectral manipulations on a spectral data set acquired from the image sensor.
In another general aspect, the invention features a pharmaceutical dosage unit manufacturing process control apparatus that includes means for simultaneously projecting a plurality of spectrally-discrete versions of a same image of a flow of pharmaceutical dosage units onto an image sensor, and means for processing the images acquired by the means for acquiring. In preferred embodiments, the means for simultaneously projecting can include a filter having filter characteristics that vary along the direction of flow of pharmaceutical dosage units.
In a further general aspect, the invention features a pharmaceutical dosage unit manufacturing process control method that includes simultaneously projecting a plurality of spectrally-discrete versions of a same image of a flow of pharmaceutical dosage units onto an image sensor, acquiring a plurality of multi-pixel images of the flow of pharmaceutical dosage units, processing the images acquired in the step of acquiring, and providing an indication about the flow of pharmaceutical dosage units based on the step of processing. In preferred embodiments, the step of simultaneously projecting can include a step of filtering.
In another general aspect, the invention features a pharmaceutical dosage unit manufacturing process control apparatus. This apparatus comprises an image sensor including an array of detector elements located generally along an axis that is perpendicular to a direction of a flow of pharmaceutical dosage units. A spectrally selective element is located in an optical path between a radiation source, the flow of pharmaceutical dosage units, and the image sensor. A spectral processor is responsive to an output of the image sensor and having an output port. In preferred embodiments, the spectral processor can include a color mapping module operative to map spectral information into a color image including differently colored areas that correspond to different parts of the flow of pharmaceutical dosage units having differing responses to different wavelengths. An additional processor can be operative to evaluate the differently colored areas, with the additional processor having an input responsive to the mapping module and an output for providing information about the areas. The mapping module can be operative to shift a plurality of the wavelengths in a similar manner. The spectral processor can include a spectral comparison module operative to compare spectral signatures from a library of known spectral signatures with spectral information acquired from the image sensor. The spectral comparison module can be operative to perform spectral comparisons between the spectral information acquired from the image sensor and spectral signatures for known ingredients in a pharmaceutical composition of the dosage units. The processor can be operative to receive, identify, and store newly detected spectral signatures reported by the spectral comparison module. The library of known spectral signatures can include a plurality of spectral signatures for known defects. The processor can be operative to receive, identify, and store spectral signatures for newly detected defects reported by the spectral comparison module. The spectral processor can include a spectral comparison module operative to compare spectral information received by the image sensor from a reference sample located proximate the flow of pharmaceutical dosage units with spectral information received by the image sensor from the flow of pharmaceutical dosage units. The image sensor can be a two-dimensional array sensor that further includes detectors located generally along an axis that is parallel to the direction of the flow of pharmaceutical dosage units. The spectrally selective element can include a diffraction grating. The spectral processor can include a color mapping module operative to map spectral information into a color image including differently colored areas that correspond to different parts of the flow of pharmaceutical dosage units having differing responses to different wavelengths. An image processor can be responsive to the output port of the spectral processor and operative to evaluate information from the spectral processor. The image sensor can be an infrared image sensor. The image sensor can be a near infrared image sensor. The radiation source can be directed at the flow of pharmaceutical dosage units at a position to which the image sensor is responsive. The flow of pharmaceutical dosage units can include a series of dosage units located in rows generally perpendicular to the direction of the flow of pharmaceutical dosage units, with the image sensor including, for each of the dosage units in a row, a plurality of detectors along the axis that is perpendicular to the direction of the flow of pharmaceutical dosage units. The spectral processor can be a real-time processor operative to process the images at a rate that is at least equal to a rate at which images are acquired by the image sensor. The spectral processor can be operative to sequentiall -process spectral data for each line image acquired by the image sensor. The spectral processor can be operative to receive image data from the image sensor at a rate that is independent of a rate of advance of the flow of pharmaceutical dosage units. The spectral processor can be operative to receive image data from the image sensor at a rate that is independent of a rate of advance of the flow of pharmaceutical dosage units. The spectral processor can be operative to perform univariate spectral manipulations on a spectral data set acquired from the image sensor. The spectral processor can be operative to perform multivariate spectral manipulations on a spectral data set acquired from the image sensor. The spectrally selective element can be a filter having filter characteristics that vary along the direction of flow of pharmaceutical dosage units. The spectrally selective element can be a continuously gradeable filter. The spectrally selective element can include a system that simultaneously projects a plurality of spectrally-discrete versions of a same image onto the image sensor.
In another general aspect, the invention features a pharmaceutical dosage unit manufacturing process control apparatus that includes means for acquiring a plurality of multi- pixel images of a flow of pharmaceutical dosage units at different wavelengths along an axis that is perpendicular to a direction of the flow of pharmaceutical dosage units, and means for processing the images acquired by the means for acquiring.
In a further general aspect, the invention features a pharmaceutical dosage unit manufacturing process control method including acquiring a plurality of multi-pixel images of a flow of pharmaceutical dosage units at different wavelengths along an axis that is perpendicular to a direction of the flow of pharmaceutical dosage units, processing the images acquired in the step of acquiring, and providing an indication about the flow of pharmaceutical dosage units based on the step of processing.
In another general aspect, the invention features a pharmaceutical dosage unit manufacturing process control apparatus that includes means for acquiring a plurality of multi- pixel line images of a flow of pharmaceutical dosage units along an axis that is perpendicular to a direction of the flow of pharmaceutical dosage units, and means for processing the images acquired in the step of acquiring as they are received. In preferred embodiments, the means for acquiring can be operative to acquire the multi-pixel line images at a rate that is independent of a rate of advance of the flow of pharmaceutical dosage units.
In a further general aspect, the invention features a pharmaceutical dosage unit manufacturing process control method that includes acquiring a plurality of multi-pixel line images of a flow of pharmaceutical dosage units along an axis that is perpendicular to a direction of the flow of pharmaceutical dosage units, processing the images acquired in the step of acquiring as they are received, and providing an indication about the rrow of pharmaceutical dosage units based on the step of processing.
In preferred embodiments, the step of acquiring can be operative to acquire the multi- pixel line images at a rate that is independent of a rate of advance of the flow of pharmaceutical dosage units. The step of acquiring can take place through individual packaging cells for the dosage units.
In another general aspect, the invention features a process control apparatus that includes means for acquiring a spectral data set from a process flow, the spectral data set expressing the response of areas of a surface of the process flow to different wavelengths of radiation, and means for mapping the spectral data set to a color image including differently colored areas that correspond to different ones of the parts of the process flow having differing responses to the different wavelengths. In preferred embodiments, the apparatus further includes means for evaluating the differently colored areas, having an input responsive to the means for mapping and an output for providing information about the areas.
In a further general aspect, the invention features a process control method that includes acquiring a spectral data set from a process flow, the spectral data set expressing the response of areas of a surface of the process flow to different wavelengths of radiation, and mapping the spectral data set to a color image including differently colored areas that correspond to different ones of the parts of the process flow having differing responses to the different wavelengths.
In another general aspect, the invention features a process control apparatus that includes an image sensor including an array of detector elements located generally along an axis that is peφendicular to a direction of a process flow, a spectrally selective element located in an optical path between a radiation source, the flow of pharmaceutical dosage units, and the image sensor, and a spectral processor responsive to an output of the image sensor and having an output port, the spectral processor including a spectral comparison module operative to compare spectral signatures from a library of known spectral signatures with spectral information acquired from the image sensor.
In preferred embodiments, the processor can be operative to receive, identify, and store spectral signatures for newly detected defects reported by the spectral comparison module. The spectral comparison module can be operative to perform spectral comparisons between the spectral information acquired from the image sensor and spectral signatures for known defects. The spectral comparison module can be operative to perform spectral comparisons between the spectral information acquired from the image sensor and spectral signatures for known ingredients in a pharmaceutical composition of the dosage units. In a further geflδral aspect, the invention features a process control apparatus that includes means for acquiring a plurality of multi-pixel images of a process flow at different wavelengths along an axis that is peφendicular to a direction of the process flow, and means for comparing spectral signatures from a library of known spectral signatures with spectral information acquired in the step of acquiring.
In preferred embodiments, the means for comparing can be operative to receive, identify, and store spectral signatures for new defects detected by the means for comparing. The means for comparing can be operative to compare spectral signatures for known defects with the spectral information acquired in by the means for acquiring,
In another general aspect, the invention features a process control method that includes acquiring a plurality of multi-pixel images of a process flow at different wavelengths along an axis that is peφendicular to a direction of the process flow, comparing spectral signatures from a library of known spectral signatures, including a plurality of spectral signatures for known defects, with spectral information acquired in the step of acquiring, and providing an indication about the flow of pharmaceutical dosage units based on the step of processing.
In preferred embodiments, the method further includes the steps of automatically identifying and storing spectral signatures for new defects detected in the step of comparing. The step of comparing can be operative to compare spectral signatures for known defects with the spectral information acquired in the step of acquiring,
In a further general aspect, the invention features a quality control apparatus for a pharmaceutical composition that includes a two-dimensional array sensor including a two- dimensional array of detector elements, a spectrally selective element located in an optical path between a radiation source, the flow of pharmaceutical dosage units, and the two-dimensional array sensor, and a spectral processor responsive to an output of the array sensor and having an output port. The spectral processor includes a mapping module operative to map spectral information into an image including different areas corresponding to different components of the pharmaceutical composition having differing responses to different wavelengths.
In preferred embodiments, the spectral processor can include a spectral comparison module operative to compare one or more known spectral signatures with spectral information acquired from the array sensor. The spectral comparison module can be operative to perform spectral comparisons between the spectral information acquired from the array sensor and spectral signatures for at least one known ingredient in the pharmaceutical composition. The spectral comparison module can be operative to perform spectral comparisons between the spectral information acquired from the array sensor and spectral signatures for a plurality of known ingredients in the pharmaceutical composition. The spectral processor can include a spectral comparison module operative to compare spectral information received by the array sensor from a reference sample with spectral information received by the array sensor. The spectrally selective element can include a diffraction grating. The apparatus can further include an image processor responsive to the output port of the spectral processor and operative to evaluate information from the spectral processor. The array sensor can be an infrared image sensor. The array sensor can be a near infrared image sensor. The radiation source can be directed at the pharmaceutical composition at a position to which the array sensor is responsive. The radiation source can be an infrared radiation source. The spectral processor can be operative to perform spectral manipulations on a spectral data set that includes image values at different wavelengths for each of a plurality of pixels corresponding to ones of the detector elements in the detector array. The quality control apparatus can be part of an on-line monitoring apparatus that continuously monitors a moving process web. The quality control apparatus can be operative to detect product defects that include non-uniformity of a size of capsules transported by the web. The quality control apparatus can be operative to detect product defects that include contamination or damage. The quality control apparatus can be operative to detect product defects that include product non-uniformity. The mapping module can be a color mapping module. The apparatus can further include an additional processor operative to evaluate the different areas, with the additional processor having an input responsive to the mapping module and an output for providing information about the areas. The spectral processor can be operative to perform univariate spectral manipulations on a spectral data set acquired from the array sensor. The spectral processor can be operative to perform multivariate spectral manipulations on a spectral data set acquired from the array sensor. The spectrally selective element can include a system that simultaneously projects a plurality of spectrally-discrete versions of a same image onto the array sensor.
In another general aspect, the invention features a quality control apparatus for a pharmaceutical composition that includes means for acquiring a two-dimensional spectral data set expressing the response of areas of a surface to different wavelengths of radiation, and means for mapping the spectral data set to an image including different areas that correspond to different components of the pharmaceutical composition having differing responses to different wavelengths.
In preferred embodiments, the means for acquiring can include means for selecting spectral components of radiation received from ingredients of the pharmaceutical composition. The means for processing can include means for comparing spectral signatures from a library of known spectral signatures with spectral information acquired in the step of acquiring. In a further general aspect, the invention features a quality control method for a pharmaceutical composition that includes acquiring a spectral data set expressing the response of areas of a surface to different wavelengths of radiation, and mapping the spectral data set to a color image including differently colored areas that correspond to different ones of the parts of surface having differing responses to the different wavelengths. In preferred embodiments, the method can further include the step of comparing spectral signatures from a library of known spectral signatures including signatures for one or more components of the pharmaceutical composition.
Systems according to the invention are advantageous in that they can continuously test the actual composition of each dosage unit within its packaging. Such systems can therefore screen for errors in coloring of ingredients, for contamination or breakdown that occurs independent of coloring, and for other types of errors that might not otherwise be detected. And because systems according to the invention can perform their composition measurements through the end-user package walls, they can detect contamination or damage that occurs during packaging.
Performing composition analysis by comparing spectral information with libraries of known spectral signatures, allows small concentrations of potentially dangerous contaminants, such as potent toxins, to be detected. Without being correlated to a specific spectral signature, such small concentrations might have little effect on prior art process monitoring methods, and might therefore be dismissed as within an error margin.
Performing composition analysis by comparing spectral information with libraries of known spectral signatures may also allow for the detection of unexpected components. Comparing acquired spectral information with libraries of components may uncover contaminants not normally associated with the process. This may allow a manufacturer to avert hazards that arise out of unforseen circumstances, such as supplier errors or deliberate tampering.
Performing composition analysis by comparing spectral information with libraries of known spectral signatures may further allow for the detection of subtle shifts in the process. Because relative quantities of ingredients can be directly measured, a change in the ratio of these ingredients can be detected. While such changes may not warrant rejection of the products, they may allow the process to be optimized and prevent the process from drifting out of its intending operating range.
Systems according to the invention may also be advantageous in that they can allow a process engineer to select optimal process variables to monitor. By mapping selected spectral information into an image, which is then processed by an image processor, systems according to the invention can apply the image processing resources to the spectrat data that correlates best to known and predicted failure modes. And because the system acquires information about a large number of wavelengths simultaneously, a system operator can try a number of different approaches to achieve the best results.
Brief Description of the Drawings
Fig. 1 is a diagram of an embodiment of a pharmaceutical dosage unit manufacturing process control system according to the invention, including a perspective portion illustrating the relationship between the image sensor, the spectrally selective element, and the process stream;
Fig. 2 is a plan view diagram of an image sensor for use with the process control system of Fig. 1;
Fig. 3 is a plan view diagram illustrating output of the system of Fig. 1;
Fig. 4 is a flowchart illustrating the operation of the embodiment of Fig. 1; and
Fig. 5 is a diagram of a second embodiment of a pharmaceutical dosage unit manufacturing process control system according to the invention, including a perspective portion illustrating the relationship between the image sensor, the spectrally selective element, and the process stream.
In the figures, like reference numbers represent like elements.
Description of an Illustrative Embodiment
Referring to Fig. 1, a pharmaceutical dosage unit manufacturing process control system according to the invention features an image sensor 10 and a spectrally selective element 12 facing a web 16 that carries a series of parallel rows of pharmaceutical dosage units 18, such as capsules, tablets, pellets, ampoules, or vials, in a process flow direction. For example, the web can carry a continuous stream of blister-packaged tablets from the output of a packaging machine. The image sensor is a multi-element sensor that includes at least a series of adjacent sensing elements located generally along an axis that is peφendicular to the flow direction. The spectrally selective element is a wavelength separating element, and is preferably a dispersive element, such as a diffraction grating or a prism-based monochromator.
Referring to Figs. 1-2, the image sensor 10 is preferably a two-dimensional array sensor that includes a two-dimensional array of detector elements made up of a series of lines of elements (Al - An, Bl - Bn, ... Nl - Nn) that are each located generally along an axis that is peφendicular to the flow direction. The image sensor can include an array of integrated semiconductor elements, such as a Charge-Coupled Device (CCD) array, and is preferably sensitive to infrared radiation. Uncooled Idium-Galium-Arsenide (InGaAs) arrays, which are sensitive to near infrarrd wavelengths, are suitable image sensors, alnrough sensitivity to longer wavelengths would be desirable. It is contemplated that the sensors should preferably have dimensions of at least 64 x 64 or even 256 x 256. Where such sensors are not square, they should be oriented with their longer dimension in the direction of the process flow, as spectral information appears to be typically more important than spatial information given the nature of pharmaceutical mass-production equipment.
The system also includes an image acquisition interface 22 having an input port responsive to an output port of the image sensor 10. The image acquisition interface receives and/or formats image signals from the image sensor. It can include an off-the shelf frame buffer card with a 12-16 bit dynamic range, such as are available from Matrox Electronic Systems Ltd. of Montreal, Canada, and Dipix Technologies, of Ottawa, Canada.
A spectral processor 26 has an input responsive to the image acquisition interface 22. This spectral processor has a control output provided to a source control interface 20, which can power and control an illumination source 14. The illumination source for near infrared measurements is preferably a Quartz-Tungsten-Halide lamp.
The spectral processor 26 is also operatively connected to a standard input/output (IO) interface 30 and to a local spectral library 24. The local spectral library includes locally-stored spectral signatures for known process components. These components can include ingredients, process products, or results of process defects or contamination. The IO interface can also operatively connect the spectral processor to a remote spectral library 28.
The spectral processor 26 is operatively connected to an image processor 32 as well. The image processor can be an off-the-shelf programmable industrial image processor, that includes special-puφose image processing hardware and image evaluation routines that are operative to evaluate shapes and colors of manufactured objects in industrial environments. Such systems are available from, for example, Cognex, Inc.
In one embodiment, the system is based on the so-called IBM-PC architecture. The image acquisition interface 22, IO interface 30, and image processor 32 each occupy expansion slots on the system bus. The spectral processor is implemented using special-puφose spectral processing routines loaded on the host processor, and the local spectral library is stored in local mass storage, such as disk storage. Of course, other structures can be used to implement systems according to the invention, including various combinations of dedicated hardware and special-puφose software running on general-puφose hardware. In addition, the various elements and steps described can be reorganized, divided, and combined in different ways without departing from the scope and spirit of the invention. For example, many of the separate operations described arjove can be performed simultaneously according to well-known pipelining and parallel processing principles.
In operation, referring to Figs. 1-4, the spectrally selective element 12 is sensitive to the radiation reflected off of a line across the process web 16, and collimated by a first-stage optic, such as a lens (not shown). The spectrally selective element separates the spectral components of the reflected radiation along the axis of the process flow. As a result, the successive lines Al - An, Bl - Bn, ... Nl - Nn of the image sensor are exposed to spectral components of the radiation that are of successively higher or lower wavelengths, depending on the relative orientation of the spectrally selective element and the image sensor. In one embodiment, a portion of the line image extends beyond the web to overlap with a stationary reference sample 19 located adjacent the web. This implementation can allow for the removal of transfer of calibration requirements between systems that collect pure component, spectra for spectral comparison.
At a predetermined repetition rate, the image acquisition interface 22 acquires a data set representative of the radiation incident on the image sensor (i.e., a spectral line image — step 40). This data set includes image values for each of the pixels along the imaged line on the process web at a number of different wavelengths. In the case of a 256 x 256 array, intensity values at 256 different wavelengths will be stored for each of 256 points on the imaged line. Once it has been acquired, the image acquisition interface transfers this data set to the spectral processor 26.
The spectral processor 26 then evaluates the acquired spectral line image (step 42). This evaluation can include a variety of univariate and multivariate spectral manipulations. These can include comparing received spectral information with spectral signatures stored in the library, comparing received spectral information attributable to manufactured dosage units with information attributable to the reference sample, or evaluating simplified test functions, such as looking for the absence of a particular wavelength or combination of wavelengths. Multivariate spectral manipulations are discussed in more detail in "Multivariate Image Analysis," by Paul Geladi and Hans, Grahn, available from John Wiley, ISBN No. 0-471-93001-6, which is herein incoφorated by reference.
As a result of its evaluation, the spectral processor 26 may detect known components (step 44) and or unknown components (step 46). If an unknown component is detected, the system records a spectral signature entry for the new component type in the local spectral library 24 (step 48). The system can also attempt to identify the newly detected component in an extended or remote library 28, such as by accessing it through a telephone line or computer network (step 50). The system then flags the detection of the new component to the system operator, and reports any retrieved candidate identities (step 52). Once component identification is complete, the system maps ffle different detected components into a color (such as grayscale) line image (step 54). As the system processes further spectral line images, it accumulates a two-dimensional colored image frame. When complete, this image can be transferred to the image processor (step 58), which evaluates the shape and color of the dosage units (step 60), issues rejection signals for rejected dosage units, and compiles operation logs.
As shown in Fig. 3, the color image will resemble the process web, although it may be stretched or squeezed in the direction of the process flow, depending on the acquisition rate. The image can include a color that represents the composition of the web 16. It will can also include colors that represent known good components 18A, colors that represent known defect components 18B, and colors that represent unknown components 18C. The mapping can also take the form of a spectral shift, in which some or all of the acquired spectral components are shifted in a similar manner, preserving the relationship between wavelengths. Note that because the image maps components to colors, it provides information about spatial distribution of the pharmaceutical composition in addition to identifying its components.
While the system can operate in real-time to detect defective products, its results can also be analyzed further off-line. For example, some or all of the spectral data sets, or running averages derived from these data sets can be stored and periodically compared with extensive off-line databases of spectral signatures to detect possible new contaminants. Relative spectral intensities arising from relative amounts of reagents or ingredients can also be computed to determine if the process is optimally adjusted.
Note that the system presented above is self-scanning. Although it can be synchronized with the process by a sensor, such synchronization is not required. The system can therefore be easily retrofit to existing installations and does not require any moving parts.
The acquisition method employed by the process control system can also be computationally efficient. Since data is acquired and spectrally processed on a line-by-line basis, the spectral processor does not have to store large amounts of intermediate results. Once a line has been mapped to a colored line image, all of the acquired data and intermediate results can be discarded, and a new line processed. This can allow the system to operate in real time with relatively simple computer components, keeping the overall system cost low.
Referring to Fig. 5, a second embodiment of a pharmaceutical dosage unit manufacturing process control system according to the invention includes a variable-bandpass filter 12a between the two-dimensional array sensor and the process stream. This filter has a narrow pass- band with a center wavelength that varies along the process direction. The leading edge A of the filter passes shorter wavelengths, and as the distance from the leading edge along the process flow direction increases, the filter passes successively longer wavelengths. At the trailing edge N of the filter, the filter passes a narrow range of the longest wavelengths. The orientation of the filter can also be reversed, so that the pass-band center wavelength decreases along the process flow direction. Although the filter has been illustrated as a series of strips located peφendicular to the process flow direction, it can be manufactured in practice by continuously varying the dielectric thickness in an interference filter. Preferably, the filter should have a range of pass- bands that matches the range of the camera. Suitable filters are available, for example, from Optical Coatings Laboratory, Inc. of Santa Rosa, California.
In operation of this embodiment, acquisition interface 22 acquires data representing a series of variably- filtered, two-dimensional images. These two-dimensional images each include image values for the pixels in a series of adjacent lines peφendicular to the process web. Because of the action of the variable-bandpass filter, the detected line images that make up each two-dimensional image will have a spectral content that varies along the process direction.
The variably filtered images are combined as they are acquired in order to obtain full- range spectral images. As each imaged line progresses along the web, each successive line ( l ... Al) of elements in the array sensor 10 will sense radiation that has been filtered through a corresponding line (N ... A) of the filter. These individual line images can be assembled to create a full-spectrum line image. The assembly can take place by itself, or in combination with other operations, such as digital filtering operations. This embodiment is particularly advantageous because the variable-bandpass filter is relatively inexpensive and robust.
Another approach involves the use of an optical system that simultaneously projects a number of spectrally-discrete versions of the same two-dimensional image onto the array sensor 10. Such systems are described in PCT application No. PCT US98/14218 published under No. WO09902950, which are herein incoφorated by reference. The use of these systems is advantageous in that they allow high data throughputs for a given web speed, without adding moving parts. Systems of this type are available from Optical Insights, Inc of Tucson, Arizona.
A further embodiment employs multi-source arrays to provide successive illumination at different wavelengths and thereby obtain spectral information from the process. Such arrays are described in a copending provisional application entitled "Multi-Source Arrays," filed on the same day as this application, and herein incoφorated by reference.
The present invention has now been described in connection with a number of specific embodiments thereof. However, numerous modifications which are contemplated as falling within the scope of the present invention should now be apparent to those skilled in the art. For example, aspects of the invention may also be applicable to other types of manufacturing processes, such in detecting the presence of undesirable by-products in the manufacture of plastic articles. In addition, while a two-dimensional image sensor wTTh a dispersive or graded spectrally selective element is at present contemplated to be the best approach to acquiring line image data, a one-dimensional image sensor coupled with a high-speed filtering system might allow a suitable amount of data to be acquired in some circumstances. Therefore, it is intended that the scope of the present invention be limited only by the scope of the claims appended hereto. In addition, the order of presentation of the claims should not be construed to limit the scope of any particular term in the claims. What is claimed is:

Claims

1. A pharmaceutical dosage unit manufacturing process control apparatus, comprising: an image sensor including an array of detector elements located generally proximate a flow of pharmaceutical dosage units, a spectrally selective element that simultaneously projects a plurality of spectrally- discrete versions of a same image of the flow of pharmaceutical dosage units onto the image sensor, and a spectral processor responsive to an output of the array sensor and having an output port.
2. The apparatus of claim 1 wherein the spectrally selective element is a filter having filter characteristics that vary along the direction of flow of pharmaceutical dosage units.
3. The apparatus of claim 1 wherein the spectrally selective element is a continuously gradeable filter.
4. The apparatus of claim 1 wherein the spectral processor includes a color mapping module operative to map spectral information into a color image including differently colored areas that correspond to different parts of the flow of pharmaceutical dosage units having differing responses to different wavelengths.
5. The apparatus of claim 4 further including an additional processor operative to evaluate the differently colored areas, the additional processor having an input responsive to the mapping module and an output for providing information about the areas.
6. The apparatus of claim 4 wherein the mapping module is operative to shift a plurality of the wavelengths in a similar manner.
7. The apparatus of claim 1 wherein the spectral processor includes a spectral comparison module operative to compare spectral signatures from a library of known spectral signatures with spectral information acquired from the image sensor.
8. The apparatus of claim 7 wherein the spectral comparison module is operative to perform spectral comparisons between the spectral information acquired from the image sensor and spectral signaturesTor known ingredients in a pharmaceutical composition of the dosage units.
9. The apparatus of claim 7 wherein the processor is operative to receive, identify, and store newly detected spectral signatures reported by the spectral comparison module.
10. The apparatus of claim 7 wherein the library of known spectral signatures includes a plurality of spectral signatures for known defects.
11. The apparatus of claim 10 wherein the processor is operative to receive, identify, and store spectral signatures for newly detected defects reported by the spectral comparison module.
12. The apparatus of claim 1 wherein the spectral processor includes a spectral comparison module operative to compare spectral information received by the image sensor from a reference sample located proximate the flow of pharmaceutical dosage units with spectral information received by the image sensor from the flow of pharmaceutical dosage units.
13. The apparatus of claim 1 wherein the image sensor is a two-dimensional array sensor that further includes detectors located generally along an axis that is parallel to the direction of the flow of pharmaceutical dosage units.
14. The apparatus of claim 13 wherein the spectrally selective element includes a diffraction grating.
15. The apparatus of claim 13 wherein the spectral processor includes a color mapping module operative to map spectral information into a color image including differently colored areas that correspond to different parts of the flow of pharmaceutical dosage units having differing responses to different wavelengths.
16. The apparatus of claim 1 further including an image processor responsive to the output port of the spectral processor and operative to evaluate information from the spectral processor.
17. The apparatus of claim 1 wherein the image sensor is an infrared image sensor.
18. The apparatus of claim 1 wherein the image sensor is a nδSr infrared image sensor.
19. The apparatus of claim 1 further including a radiation source directed at the flow of pharmaceutical dosage units at a position to which the array sensor is responsive.
20. The apparatus of claim 19 wherein the radiation source is an infrared radiation source.
21. The apparatus of claim 1 wherein the flow of pharmaceutical dosage units includes a series of dosage units located in rows generally peφendicular to the direction of the flow of pharmaceutical dosage units and wherein the image sensor includes, for each of the dosage units in a row, a plurality of detectors along the axis that is peφendicular to the direction of the flow of pharmaceutical dosage units.
22. The apparatus of claim 1 wherein the spectral processor is a real-time processor operative to process the images at a rate that is at least equal to a rate at which images are acquired by the image sensor.
23. The apparatus of claim 22 wherein the spectral processor is operative to sequentially process spectral data for each line image acquired by the image sensor.
24. The apparatus of claim 23 wherein the spectral processor is operative to receive image data from the image sensor at a rate that is independent of a rate of advance of the flow of pharmaceutical dosage units.
25. The apparatus of claim 1 wherein the spectral processor is operative to receive image data from the image sensor at a rate that is independent of a rate of advance of the flow of pharmaceutical dosage units.
26. The apparatus of claim 1 wherein the spectral processor is operative to perform univariate spectral manipulations on a spectral data set acquired from the image sensor.
27. The apparatus of claim 1 wherein the spectral processor is operative to perform multivariate spectral manipulations on a spectral data set acquired from the image sensor.
28. A pharmaceutical dosage unit manufacturing process control apparatus, comprising: means for simultaneously projecting a plurality of spectrally-discrete versions of a same image of a flow of pharmaceutical dosage units onto an image sensor, and means for processing the images acquired by the means for acquiring.
29. The apparatus of claim 28 wherein the means for simultaneously projecting include a filter having filter characteristics that vary along the direction of flow of pharmaceutical dosage units.
30. A pharmaceutical dosage unit manufacturing process control method, comprising: simultaneously projecting a plurality of spectrally-discrete versions of a same image of a flow of pharmaceutical dosage units onto an image sensor, acquiring a plurality of multi-pixel images of the flow of pharmaceutical dosage units, processing the images acquired in the step of acquiring, and providing an indication about the flow of pharmaceutical dosage units based on the step of processing.
31. The method of claim 30 wherein the step of simultaneously projecting includes a step of filtering.
PCT/US2000/019273 1999-07-14 2000-07-14 High-volume on-line spectroscopic composition testing of manufactured pharmaceutical dosage units WO2001003646A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP00950359A EP1218705A4 (en) 1999-07-14 2000-07-14 High-volume on-line spectroscopic composition testing of manufactured pharmaceutical dosage units

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14380199P 1999-07-14 1999-07-14
US60/143,801 1999-07-14
US09/507,293 US6690464B1 (en) 1999-02-19 2000-02-18 High-volume on-line spectroscopic composition testing of manufactured pharmaceutical dosage units
US09/507,293 2000-02-18

Publications (2)

Publication Number Publication Date
WO2001003646A2 true WO2001003646A2 (en) 2001-01-18
WO2001003646A3 WO2001003646A3 (en) 2001-05-25

Family

ID=26841404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/019273 WO2001003646A2 (en) 1999-07-14 2000-07-14 High-volume on-line spectroscopic composition testing of manufactured pharmaceutical dosage units

Country Status (2)

Country Link
EP (1) EP1218705A4 (en)
WO (1) WO2001003646A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002065101A2 (en) * 2001-02-12 2002-08-22 Analytical Spectral Devices, Inc. System and method for the collection of spectral image data
US6667802B2 (en) 2001-02-12 2003-12-23 Analytical Spectral Devices, Inc. System and method for self-referencing calibration
US6765212B2 (en) 2001-02-12 2004-07-20 Analytical Spectral Devices, Inc. System and method for combining reflectance data
US6894772B2 (en) 2001-02-12 2005-05-17 Analytical Spectral Devices System and method for grouping reflectance data
EP2011047A2 (en) * 2006-04-07 2009-01-07 University of Maryland, Baltimore Product authentication
WO2013154661A1 (en) * 2012-04-13 2013-10-17 Raytheon Company Adaptive multispectral imaging
US8719043B2 (en) 2003-09-22 2014-05-06 University Of Maryland, Baltimore Drug authentication
EP2728341A4 (en) * 2011-06-28 2015-04-22 Otsuka Pharma Co Ltd Drug inspection device and drug inspection method
WO2015136620A1 (en) * 2014-03-11 2015-09-17 株式会社東芝 Tablet inspection device, tablet inspection method, and tablet inspection program
WO2022117874A1 (en) * 2020-12-03 2022-06-09 Ziuz Holding B.V. Inspecting medicine objects based on hyperspectral imaging
NL2027213B1 (en) * 2020-12-03 2022-07-06 Ziuz Holding B V Inspecting medicine objects based on hyperspectral imaging

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166755A (en) 1990-05-23 1992-11-24 Nahum Gat Spectrometer apparatus
US5638657A (en) 1994-05-09 1997-06-17 Merck & Co., Inc. System and method for automatically feeding, inspecting and diverting tablets for continuous filling of tablet containers
EP0887638A1 (en) 1997-06-24 1998-12-30 The Automation Partnership (Cambridge) Limited Product integrity verification apparatus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929398A (en) * 1971-08-18 1975-12-30 Harry E Bates High speed optical wavelength detection system
US4278538A (en) * 1979-04-10 1981-07-14 Western Electric Company, Inc. Methods and apparatus for sorting workpieces according to their color signature
US5668373A (en) * 1996-04-26 1997-09-16 Trustees Of Tufts College Methods and apparatus for analysis of complex mixtures
DE69841107D1 (en) * 1997-07-12 2009-10-08 Roper Ind Inc MULTISPEKTRAL TWO-DIMENSIONAL IMAGE PROBES SPECTROMETER
SE512098C2 (en) * 1998-05-19 2000-01-24 Agrovision Ab Concentration determination of one component in a mixture of at least two components

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166755A (en) 1990-05-23 1992-11-24 Nahum Gat Spectrometer apparatus
US5638657A (en) 1994-05-09 1997-06-17 Merck & Co., Inc. System and method for automatically feeding, inspecting and diverting tablets for continuous filling of tablet containers
EP0887638A1 (en) 1997-06-24 1998-12-30 The Automation Partnership (Cambridge) Limited Product integrity verification apparatus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1218705A4

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002065101A2 (en) * 2001-02-12 2002-08-22 Analytical Spectral Devices, Inc. System and method for the collection of spectral image data
WO2002065101A3 (en) * 2001-02-12 2003-02-27 Analytical Spectral Devices In System and method for the collection of spectral image data
US6667802B2 (en) 2001-02-12 2003-12-23 Analytical Spectral Devices, Inc. System and method for self-referencing calibration
US6765212B2 (en) 2001-02-12 2004-07-20 Analytical Spectral Devices, Inc. System and method for combining reflectance data
US6853447B2 (en) 2001-02-12 2005-02-08 Analytical Spectral Devices, Inc. System and method for the collection of spectral image data
US6894772B2 (en) 2001-02-12 2005-05-17 Analytical Spectral Devices System and method for grouping reflectance data
US8719043B2 (en) 2003-09-22 2014-05-06 University Of Maryland, Baltimore Drug authentication
EP2011047A4 (en) * 2006-04-07 2010-09-15 Univ Maryland Product authentication
EP2011047A2 (en) * 2006-04-07 2009-01-07 University of Maryland, Baltimore Product authentication
EP2728341A4 (en) * 2011-06-28 2015-04-22 Otsuka Pharma Co Ltd Drug inspection device and drug inspection method
WO2013154661A1 (en) * 2012-04-13 2013-10-17 Raytheon Company Adaptive multispectral imaging
US8964182B2 (en) 2012-04-13 2015-02-24 Raytheon Company Adaptive multispectral imaging
WO2015136620A1 (en) * 2014-03-11 2015-09-17 株式会社東芝 Tablet inspection device, tablet inspection method, and tablet inspection program
WO2022117874A1 (en) * 2020-12-03 2022-06-09 Ziuz Holding B.V. Inspecting medicine objects based on hyperspectral imaging
NL2027213B1 (en) * 2020-12-03 2022-07-06 Ziuz Holding B V Inspecting medicine objects based on hyperspectral imaging

Also Published As

Publication number Publication date
EP1218705A2 (en) 2002-07-03
WO2001003646A3 (en) 2001-05-25
EP1218705A4 (en) 2009-07-29

Similar Documents

Publication Publication Date Title
US6690464B1 (en) High-volume on-line spectroscopic composition testing of manufactured pharmaceutical dosage units
US7528957B2 (en) Spectrometric process monitoring
US6853447B2 (en) System and method for the collection of spectral image data
US6894772B2 (en) System and method for grouping reflectance data
US5120126A (en) System for non-contact colored label identification and inspection and method therefor
US6765212B2 (en) System and method for combining reflectance data
CA2211785C (en) Real-time on-line analysis of organic and non-organic compounds for food, fertilizers and pharmaceutical products
EP1218705A2 (en) High-volume on-line spectroscopic composition testing of manufactured pharmaceutical dosage units
US6556291B2 (en) Defect inspection method and defect inspection apparatus
WO2016043397A1 (en) Glass defect detection method and apparatus using hyperspectral imaging technique
JP7163060B2 (en) Systems and methods for high-speed, low-noise, in-process, hyperspectral, non-destructive evaluation of rapid composite manufacturing
US20020135769A1 (en) Hybrid-scanning spectrometer
EP0965393B1 (en) Method for discrimination of product units and apparatus therefor
WO2002007066A1 (en) High-volume on-line spectroscopic composition testing of pharmaceutical dosage units
JP2019148607A (en) Inspection device
US6954271B2 (en) System and method for multiplexing inputs into a single spectrometer
KR20030048153A (en) A method and device for recording images of grains from cereals to detect cracking
EP1095246B1 (en) High-throughput infrared spectroscopy
US20080130001A1 (en) Hybrid-imaging spectrometer
US8213011B2 (en) Spatial imaging/imaging spectroscopy system and method
JPH04194712A (en) Spectrophotometer
JPH0359443A (en) Device for spectrochemical analysis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): BR CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): BR CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000950359

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000950359

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP